Patents by Inventor Adam S. Lazorchak

Adam S. Lazorchak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Treatment of Cancer
    Publication number: 20230372319
    Abstract: The present disclosure relates to combination therapies useful for the treatment of cancer. In particular, the disclosure relates to the combined use of a PD-1 inhibitor, a TGFbeta inhibitor, and a PARP inhibitor to treat cancer.
    Type: Application
    Filed: November 1, 2021
    Publication date: November 23, 2023
    Inventors: Yan Lan, Adam S. Lazorchak
  • CONJOINT THERAPIES FOR IMMUNOMODULATION
    Publication number: 20230081191
    Abstract: The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: October 5, 2022
    Publication date: March 16, 2023
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
  • COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20230044248
    Abstract: The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGF? inhibitor, an ATM inhibitor and radiation to treat cancer.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 9, 2023
    Applicants: ARES TRADING S.A., GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LTD.
    Inventors: Yan LAN, Adam S. LAZORCHAK
  • Conjoint therapies for immunomodulation
    Patent number: 11497735
    Abstract: The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignees: Aurigene Discovery Technologies Limited, Curis, Inc.
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant
  • CONJOINT THERAPIES FOR IMMUNOMODULATION
    Publication number: 20200289477
    Abstract: The present disclosure relates to methods comprising administering compounds that inhibit VISTA and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways with a compound that inhibits TIM-3 and PD-1 (e.g., PD-1, PD-L1, or PD-L2) pathways. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by VISTA, TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: October 31, 2018
    Publication date: September 17, 2020
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Raghuveer K. Ramachandra, Adam S. Lazorchak, Timothy L. Wyant